Anales Oftalmológicos

85 Propuesta de protocolo de uso de implante de dexametasona intravítreo en pacientes con edema macular diabético en el Servicio de Oftalmología del Hospital San Juan de Dios patients with diabetic macular edema. BMC Ophthalmol 2012; 12: 11. 22. Avery RL and Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and metaanalysis. JAMA Ophthalmol 2016; 134(1): 21–29. 23. Boyer DS, Yoon YH, Belfort R, et al. Three- year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121(10): 1904–1914. 24. Malclès A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (OZURDEX): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 2017; 37: 1352–1359. 25. Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006; 142(5): 794–799. 26. Lambiase A, Abdolrahimzadeh S and Recupero SM. An update on intravitreal implants in use for eye disorders. Drugs Today 2014; 50(3): 239–249. 27. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117(6): 1134–1146. 28. Voykov B and Bartz-Schmidt KU. Dislocation of dexamethasone intravitreous implant. Arch Ophthalmol 2012; 130(6): 706 29. Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology 2014; 121(1): 67–71. 30. Jusufbegovic D and Schaal S. Quiescent herpes simplex keratitis reactivation after intravitreal injection of dexamethasone implant. Retin Cases Brief Rep 2017; 11(4): 296–297. 31. Chang-Lin J-E, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011; 52(7): 4605– 4609. 32. Optical coherence tomography baseline predictors for initial best corrected visual acuity response to intravitreal anti vascular endothelial growth factor treatment en eyes with diabetic macular edema, the chartes study, Retina 2017: 1-10 33. Zur D. et al, OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology 2018; 125:267-275 34. Sonoda S, Sakamoto T, Yamashita T, et al. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina 2014; 34(4): 741–748. 35. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011; 152: 686–694. 36. Vujosevic S, Torresin T, Berton M, et al. Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities. Am J Ophthalmol 2017; 181: 149–155. 37. Pacella F, Ferraresi AF, Turchetti P, et al. Intravitreal injection of Ozurdex® implant in patients with persistent diabetic macular edema, with six-month follow-up. Ophthalmol Eye Dis 2016; 8: 11–16.